EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism

Linjun Ao, Raymond Noordam iD, Stella Trompet iD, Nicolien A van Vliet, Naveed Sattar iD, Nicolas Rodondi, Elisavet Moutzouri, Sarah Atighetchi, Patricia M Kearney, Terry Quinn, J Wouter Jukema, Jacobijn Gussekloo iD und 4 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag155 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Linjun Ao und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. Hauptthemen laut MEDLINE: Hypothyroidism, Biomarkers, Thyroxine, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Scholarship Council, European Union, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Randomized controlled trials (RCTs) found no cardioprotective effects of levothyroxine therapy in older adults with subclinical hypothyroidism.

Objective

The aim of this study was to assess levothyroxine effects on cardiometabolic biomarkers, which may serve as more sensitive treatment indicators.

Design

Post-hoc analysis using (baseline and 12-month) data from two double-blind RCTs in older adults (≥65 years) with subclinical hypothyroidism. Main Outcome Measure(s) Cardiometabolic biomarkers included seven clinically relevant lipid measures (apolipoprotein B (ApoB), total cholesterol (Total-C), non-high-density lipoprotein cholesterol (non-HDL-C), remnant cholesterol (RC), low-density lipoprotein cholesterol (LDL-C), HDL-C, and triglycerides (TG)) and 167 standardized metabolomic measures from nuclear magnetic resonance. Analyses were additionally stratified by baseline TSH levels.

Results

Among 286 included participants (48% women; median age 75 [70, 82] years; median baseline TSH 6.44 [5.36, 7.81] mIU/L), 142 were randomized to levothyroxine. Overall, levothyroxine showed no effects on ApoB (−0.03 [95% CI: −0.07, 0.00] g/L), Total-C (−0.17 [−0.34, 0.00] mmol/L), non-HDL-C (−0.15 [−0.31, 0.00] mmol/L), RC (−0.09 [−0.16, −0.01] mmol/L), LDL-C (−0.07 [−0.15, 0.02] mmol/L), and TG (−0.07 [−0.15, 0.01] mmol/L). In participants with baseline TSH ≥10 mIU/L (n = 27), potentially beneficial changes (P < .05, but not significant after multiple-testing correction) were observed for all clinically relevant lipids except HDL-C, as well as for ApoB-containing lipoproteins, VLDL size, and fatty acids.

Conclusion

In older adults with subclinical hypothyroidism, levothyroxine treatment showed no effects on cardiometabolic biomarkers, although potentially favorable changes in lipids and lipoproteins were observed for individuals with baseline TSH ≥10 mIU/L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypothyroidismBiomarkersThyroxineCardiovascular DiseasesHumansAgedFemaleMaleAged, 80 and overDouble-Blind MethodTreatment OutcomeAsymptomatic DiseasesLipids

Stichwörter der Autor:innen

cardiometabolic biomarkerslevothyroxinelipidsolder adultssubclinical hypothyroidism

Substanzen

BiomarkersThyroxineLipids

Autor:innen und Institutionen

  • Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
  • Department of Clinical Epidemiology, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
  • Department of Public Health and Primary Care/LUMC Campus The Hague, Leiden University Medical Center, 2333 RC Leiden, the Netherlands.
  • Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands.
  • School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow G12 8TA, UK.
  • Institute of Primary Health Care (BIHAM), University of Bern, 3012 Bern, Switzerland.

ORCID-Profile: Raymond Noordam, Stella Trompet, Naveed Sattar, Jacobijn Gussekloo, Diana van Heemst

Förderung

  • China Scholarship Council
  • European Union
  • ZonMw
  • Swiss National Science Foundation
  • Merck KGaA

Zitieren

APA

Ao, L., Noordam, R., Trompet, S., van Vliet, N. A., Sattar, N., Rodondi, N., Moutzouri, E., Atighetchi, S., Kearney, P. M., Quinn, T., Jukema, J. W., Gussekloo, J., Mooijaart, S. P., Willems van Dijk, K., Poortvliet, R. K. E., & van Heemst, D. (2026). Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag155

Vancouver

Ao L, Noordam R, Trompet S, van Vliet NA, Sattar N, Rodondi N, et al. Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag155

BibTeX
@article{Ao2026,
  author = {Ao, Linjun and Noordam, Raymond and Trompet, Stella and van Vliet, Nicolien A and Sattar, Naveed and Rodondi, Nicolas and Moutzouri, Elisavet and Atighetchi, Sarah and Kearney, Patricia M and Quinn, Terry and Jukema, J Wouter and Gussekloo, Jacobijn and Mooijaart, Simon P and Willems van Dijk, Ko and Poortvliet, Rosalinde K E and van Heemst, Diana},
  title = {Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag155}
}
Kostenlos starten →